|
Sign In to gain access to subscriptions and/or personal tools.
|
Goodbye glitazars?
Deane Conlon
MediNews (Diabetes) Limited, Edgbaston House, 3 Duchess Place, Edgbaston, Birmingham, B16 8NH, UK, production{at}bjdvd.com
Glitazars are dual peroxisome proliferator-activated receptors (PPAR) alpha/gamma agonists that improve the lipid profile and exert an antidiabetic action — similar to a combination of a fibrate and a thiazolidinedione. In May 2006 the two glitazars most advanced in development, muraglitazar (Pargluva) and tesaglitazar (Galida) were discontinued. Muraglitazar was associated with an increased incidence of heart failure and tesaglitazar was associated with decreased glomerular filtration.
Key Words: PPAR / muraglitazar • tesaglitazar.
References
- Staels B. The clinical significance of PPAR and agonism. Br J Diabetes Vasc Dis 2002;2(suppl 1):S28-S31.
- Pershadsingh HA Dual peroxisome proliferator-activated receptor-alpha/gamma agonists: in the treatment of type 2 diabetes mellitus and the metabolic syndrome. Treat Endocrinol 2006;5:89-99.[CrossRef][Medline]
[Order article via Infotrieve]
- Bailey CJ New drugs for the treatment of diabetes mellitus. In international textbook of diabetes mellitus, 3rd edn. RA DeFronzo, E Ferrannini, H Keen, P Zimmet (eds). Chichester: John Wiley, 2004, 951-79.
- Advisory Committee Briefing Document. Pargluva(muraglitazar, BMS-298585). NDA 21-865. www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B2_02_03-FDA-MedOff-Safety.pdf accessed 26th May 2006.
- Kendall DM, Rubin CJ, Mohideen P. et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23.[Abstract/Free Full Text]
- Nissen SE, Wolski K., Topol EJ Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.[Abstract/Free Full Text]
- Fagerberg B., Edwards S., Halmos T. et al. Tesaglitazar, a novel dual peroxisome proliferators-ativated receptor / agonist, dose-dependently improves the metabolic abnormalities associated with insuln resistance in a non-diabetic population. Diabetologia 2005;48:1716-25.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Goldstein BJ, Rosenstock J., Anzalone D. et al. Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes. Diabetes 2005;54(suppl 1):83-OR.
- The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study), a randomised controlled trial. Lancet 2005;366:1849-61.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dormandy JA, Charbonnel B., Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3,
135-137 (2006)
DOI: 10.1177/14746514060060030601
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
Learning from tesaglitazar
Diabetes and Vascular Disease Research,
September 1, 2007;
4(3):
161 - 162.
[PDF]
|
|
|
|
|
|
|
C. J Bailey
Treating insulin resistance: future prospects
Diabetes and Vascular Disease Research,
March 1, 2007;
4(1):
20 - 31.
[Abstract]
[PDF]
|
|
|
|
|
